|
| E676-4861 |
|
Vibrio |
Stress survival |
Preclinical (in vitro) |
Stanbery L, et al. 2017. Drug Des Devel Ther |
|
| 3-(4-CHLOROPHENYL)-N-[2-(DIMETHYLAMINO)ETHYL]-5-METHYL-2-(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE |
|
Vibrio |
Stress survival |
Preclinical (in vitro) |
Stanbery L, et al. 2017. Drug Des Devel Ther |
|
Benzimidazole 2
(internal name in literature) |
|
Vibrio |
Post-translational modification |
Preclinical (in vitro) |
Wang G, et al. 2022. ChemMedChem |
|
| (E)-3-(4-fluorophenyl)-N-[4-(1-hydroxy-5-methyl-6-nitrobenzimidazol-2-yl)phenyl]prop-2-enamide |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Kim OK, et al. 2009. J Med Chem |
|
| (E)-N-[4-(1-hydroxy-6-nitrobenzimidazol-2-yl)phenyl]-3-(4-methoxyphenyl)prop-2-enamide |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Kim OK, et al. 2009. J Med Chem |
|
| 2-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)iminoindene-1,3-dione |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| 2-hydroxy-5-{5-[(E)-{2-[(5-phenyl-2H-tetrazol-2-yl)acetyl]hydrazinylidene}methyl]furan-2-yl}benzoic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Tautz L, et al. 2005. J Biol Chem |
|
| 5-[3'-(4-methylphenyl)-1'-phenyl-5-(2-thienyl)-3,4-dihydro-1'H,2H-3,4'-bipyrazol-2-yl]-5-oxopentanoic acid |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Pan NJ, et al. 2009. Antimicrob Agents Chemother |
|
| | | |
| | | |
| | | |
| | | |
| | | |
